The Russian cancer vaccine, Enteromix, will be tested in humans after three years of successful trials with animals, according to the Federal Medical and Biological Agency.

Russian authorities have declared that the vaccine, which will be personalized, “is safe even with repeated applications for treating cancer patients.”

An official statement from the Russian Embassy in Mexico provided details about the treatment. In this regard, the Gamaleya Center, known worldwide for its contribution to the Sputnik V vaccine against Covid-19, said that trials with Enteromix will begin later this year.

The new Russian vaccine for cancer patients “uses messenger RNA (mRNA) technology, the same technology that revolutionized the creation of coronavirus vaccines,” and attacks the disease with great precision. It is said to be a personalized vaccine because it is designed to fit each patient, aiming for greater precision and reducing the typical side effects of conventional treatments.

Meanwhile, “mRNA technology trains the immune system to identify and destroy tumor cells without damaging healthy tissue or causing inflammation.”

Upon completion of animal testing, human trials will begin in late 2025. Distribution is expected to begin worldwide by the end of 2026. Enteromix will cost $3,000, but will be free for Russian citizens.

M.Pino

Source: enfarma.lat

(Reference image source: Louis Reed on Unsplash)

Visit our news channel on Google News and follow us to get accurate, interesting information and stay up to date with everything. You can also see our daily content on X/Twitter and Instagram

La entrada Russia’s cancer vaccine ready for human trials apareció primero en Bitfinance.